126
|
Fujisawa S, Maruta A, Sakai R, Taguchi J, Tomita N, Ogawa K, Kodama F, Takahashi K, Shibayama S, Kobayashi S, Ikuta K, Okubo T. Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int 1996; 9:506-8. [PMID: 8875795 DOI: 10.1007/bf00336830] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A 34-year-old man with acute myelocytic leukemia (AML: MO) and a 32-year-old woman with AML: M2 developed pure red cell aplasia (PRCA) after receiving a major ABO incompatible bone marrow transplant (BMT). The first patient responded to recombinant human erythropoietin (rhEPO) therapy, while the second did not. The second patient also received methylprednisolone (m-PSL) but developed reticulocytosis and hemolysis after the administration of m-PSL. Plasmapheresis was then performed and the patient promptly recovered from hemolysis and PRCA. We conclude that close attention must be paid when treating PRCA following major ABO-incompatible BMT with rhEPO and m-PSL, as there is always the potential for massive hemolysis.
Collapse
MESH Headings
- ABO Blood-Group System/immunology
- Acute Disease
- Adult
- Blood Group Incompatibility/etiology
- Blood Group Incompatibility/immunology
- Bone Marrow Transplantation/adverse effects
- Erythropoietin/therapeutic use
- Female
- Humans
- Leukemia, Myeloid/complications
- Leukemia, Myeloid/therapy
- Leukemia, Myeloid, Acute/complications
- Leukemia, Myeloid, Acute/therapy
- Male
- Models, Immunological
- Recombinant Proteins
- Red-Cell Aplasia, Pure/drug therapy
- Red-Cell Aplasia, Pure/etiology
- Red-Cell Aplasia, Pure/immunology
- Remission Induction
- Transplantation, Homologous/adverse effects
Collapse
|
127
|
Fujimaki K, Aratani Y, Fujisawa S, Motomura S, Okubo T, Koyama H. DNA topoisomerase II inhibitors enhance random integration of transfected vectors into human chromosomes. SOMATIC CELL AND MOLECULAR GENETICS 1996; 22:279-90. [PMID: 9000172 DOI: 10.1007/bf02369567] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
To study the involvement of DNA topoisomerase (topo) II on nonhomologous (illegitimate) recombination, we examined the effect of topo II inhibitors on random integration of exogenous vectors into human chromosomes. We transfected human cell lines PA1, HeLa and EJ-1 with linearized plasmid pSV2neo by electroporation, treated with topo II inhibitors and determined the frequency of Geneticin-resistant (G418r) colonies. We found that three topo II inhibitors, etoposide (VP-16), ICRF-193 and amsacrine (m-AMSA), greatly enhanced the frequency of G418r colonies. These effects were maximally expressed by as little as 12 hrs treatment with the drugs. Similar enhancements were found with different vectors (closed-circular and linear), different cell types, or by different transfection methods (calcium precipitation and lipofection). In contrast, the inhibitor treatments did not affect the transient expression of chloramphenicol acetyltransferase and beta-galactosidase activity following transfection with pSV2CAT and pCH110, respectively. Southern blot analysis revealed that the integration pattern of transfected pSV2neo into PA1 chromosomes was random and not characteristic for each inhibitor. These results suggest that topo II inhibitors directly act at a nonhomologous recombination reaction, promoting the integration process of transfected vectors into human chromosomes. We discuss the enhancement mechanism with a special emphasis on DNA strand breaks induced by the inhibitors.
Collapse
|
128
|
Ito S, Fujisawa S. NMR studies on dental adhesive monomer complete assignment of 13C-NMR spectrum and geometrical study of 5-methacryloylaminosalicylic acid. Dent Mater J 1996; 15:1-10. [PMID: 8940533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The 13C-NMR spectrum of 5-methacryloylaminosalicylic acid (MASA), including six quarternary carbon signals, was assigned through a combination of analyses of DEPT and 2D NMR spectra such as CH-cosy and the HMBC spectrum. A computer-generated empirical prediction of the 13C-NMR chemical shifts of MASA agreed with observed values except at C1 and 2'-CH3. The geometry of the methacryloylamino portion in polar and nonpolar media seemed to differ based on analyses of the combination of two-dimensional NOE experiments and a computer simulation using molecular orbital calculations.
Collapse
|
129
|
Fujiwara M, Yamazaki K, Okamoto M, Todoroki J, Amano T, Watanabe T, Hayashi T, Sanuki H, Nakajima N, Itoh K, Sugama H, Ichiguchi K, Murakami S, Motojima O, Yamamoto J, Satow T, Yanagi N, Imagawa S, Takahata K, Tamura H, Nishimura A, Komori A, Inoue N, Noda N, Sagara A, Kubota Y, Akaishi N, Satoh S, Tanahashi S, Chikaraishi H, Mito T, Yamada S, Yamaguchi S, Sudo S, Sato KN, Watari T, Kuroda T, Kaneko O, Ohkubo K, Kitagawa S, Ando A, Idei H, Tsumori K, Kubo S, Kumazawa R, Mutoh T, Oka Y, Sato M, Seki T, Shimozuma T, Takeiri Y, Hamada Y, Narihara K, Kawahata K, Fujisawa S, Hidekuma S, Minami T, Yamada I, Ejiri A, Tanaka K, Sasao M, Iguchi H, Watanabe KY, Yamada H, Ohyabu N, Suzuki H, Iiyoshi A. Large Helical Device (LHD) program. JOURNAL OF FUSION ENERGY 1996. [DOI: 10.1007/bf02266926] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
130
|
|
131
|
Kobayashi M, Yano K, Fujisawa S. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1996; 37:303-10. [PMID: 8847800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A number of studies have shown that regular chelation therapy with deferoxamine is effective in patients with secondary hemochromatosis. However, compliance with these regimen is difficult to obtain in most cases because long-term administration is burdensome. In 3 patients, one each with myelodysplastic syndrome, aplastic anemia and thalassemia intermedia, self-administered subcutaneous one-shot administration of deferoxamine at a dose of 500 mg once or twice daily was carried out over a long period. In all three patients serum ferritin level decreased significantly and the progression of hemochromatosis was prevented. Liver density on computed tomography scan also decreased in one patient. This regimen, in which the patient self-administered deferoxamine subcutaneously one or twice a day is seems to be the most practical method to protect against the progression of hemochromatosis.
Collapse
|
132
|
Fujisawa S, Motomura S, Fujimaki K, Mohri H, Okubo T. Chronic myelocytic leukemia following ulcerative colitis. Int J Hematol 1996; 63:241-2. [PMID: 8936338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
133
|
Hattori M, Motomura S, Tomita N, Taguchi J, Tanabe J, Sakai R, Fujisawa S, Fukawa H, Kanamori H, Mouri H, Maruta A, Kodama F, Okubo T. [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1996; 37:101-108. [PMID: 8852026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
The efficacy of various combination chemotherapies employed for the 37 patients with low-grade non-Hodgkin's lymphoma between 1981 and 1994 was evaluated retrospectively. The overall survival at 5 years was 68%. The 5-year survival of the 27 patients achieving complete response (CR) was 87%, which was significantly higher than that of 9 patients with partial response (p = 0.0005). The CR rate of stage III and IV patients was 64% for the 22 patients treated with ACOMP-B (D), and was 38% for 8 others treated with milder chemotherapy regimens including VEPA. The 22 advanced stage patients had a 5-year survival of 88% after the treatment with ACOMP-B (D) and 69% of them remained free of disease at 5 years. In this group no relapse occurred beyond 1.6 years after treatment. These findings suggest a possible role of third generation chemotherapy in the treatment of patients with advanced-stage low-grade non-Hodgkin's lymphoma.
Collapse
|
134
|
Sakai R, Maruta A, Taguchi J, Tomita N, Fujita H, Kodama F, Ogawa K, Fujisawa S, Matsuzaki M, Motomura S, Okubo T. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1996; 37:14-21. [PMID: 8683862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
We evaluated the efficacy of ganciclovir to prevent the development of cytomegalovirus interstitial pneumonitis (CMV-IP) in patients with bone marrow transplants. Of 35 patients enrolled in this study, 33 were seropositive for CMV or had seropositive donors, and two were seronegative before transplant but were positive for CMV examined by polymerase chain reaction (PCR) on days 30-37. Ganciclovir was given at a dose of 250 mg/body daily from day 30-37 to day 70. Blood, throat swabs, urine and bronchoalveolar-lavage fluid (BALF) were screened for CMV by PCR on days 30-37, 70 and 100. CVM-IP developed in two of 35 patients (5.7%) who received ganciclovir for prophylaxis, as compared with six of 39 historical controls who did not receive ganciclovir. A significant reduction of CMV detection by PCR in blood, throat swabs, and BALF was observed after administration of ganciclovir, on day 70. The incidence of neutropenia, thrombopenia and renal impairment in the study period showed no difference between the study group and the historical control. Early prophylactic use of ganciclovir appears to reduce the risk of CMV disease in allogeneic transplant recipients with positive serology or positive CMV-PCR.
Collapse
|
135
|
Kitagaki H, Fujisawa S, Watanabe K, Hayakawa K, Shiohara T. Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J Invest Dermatol 1995; 105:749-55. [PMID: 7490467 DOI: 10.1111/1523-1747.ep12325538] [Citation(s) in RCA: 145] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Repeated administration of antigen often leads to consequences different from those expected with fewer encounters with the antigen, but little attention has been paid to the effects of repeated epicutaneous application of antigens. To investigate whether repeated epicutaneous application of a contact-sensitizing agent that is generally thought to evoke a typical delayed-type hypersensitivity response could result in adverse or different consequences, BALB/c mice were sensitized with 2,4,6-trinitro-1-chlorobenzine and then were repeatedly elicited on the original sensitized site with the same antigen for 24-48 d. Detailed analyses showed that the time-course of antigen-specific hypersensitivity responses shifted from a delayed-type hypersensitivity to an immediate-type response followed by a late reaction as epicutaneous applications were repeated, a finding different from that previously reported. Development of these hypersensitivity responses was antigen specific, and this shift was associated with epidermal hyperplasia, accumulation of large numbers of mast cells and CD4+ T cells beneath the epidermis, and elevated serum levels of antigen-specific IgE. The immediate-type response to 2,4,6-trinitro-1-chlorobenzine was also induced in 2,4,6-trinitro-1-chlorobenzine-treated, genetically mast cell-deficient W/Wv mice that contained significant numbers of mast cells, but not in similarly treated S1/S1d mice devoid of mast cells. Our experimental system would provide a simple, reproducible animal model for chronic skin inflammation induced by various antigens.
Collapse
|
136
|
Fujisawa S, Maruta A, Sakai R, Ogawa K, Taguchi J, Tomita N, Kodama F, Fukawa H, Noguchi T, Matsuzaki M. [Therapy related leukemia]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1995; 36:1163-9. [PMID: 8531325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Eleven therapy related leukemias (TRL) who were hospitalized in the Department of Hematology and Chemotherapy, Kanagawa Cancer Center between October 1983 and December 1993 were identified. Six of the patients were males and five were females. Their median age was 62 years (range from 14 to 75). Three patients had previously received treatment for breast cancer and two patients for malignant lymphoma. The other patients had received treatment for lung cancer, urinary bladder cancer, gastric cancer, brain tumor, maxillary sinus cancer and macroglobulinemia, respectively. Seven patients had been treated with chemotherapy and four patients had been treated with chemotherapy and irradiation for the primary tumor. The TRL cases consisted of 8 acute non-lymphoid leukemias, two acute lymphoid leukemias and one hypoplastic leukemia, respectively. The status of primary tumors at the development of TRL was complete remission in ten patients and partial remission in one patient. Three of the 10 patients who received anti-leukemic therapy entered complete remission and the median survival time was 36 days (from 7 days to 489 days). One patient expired of pneumonia before he received anti-leukemic therapy. TRL patients showed poor response to chemotherapy and had poor prognosis. These data suggest that the use of reduced doses of carcinogenic drugs for primary tumors might be required to prevent the development of TRL.
Collapse
|
137
|
Fujisawa S, Kishi E, Sugawara Y, Morita S. Load dependence of two-dimensional atomic-scale friction. PHYSICAL REVIEW. B, CONDENSED MATTER 1995; 52:5302-5305. [PMID: 9981718 DOI: 10.1103/physrevb.52.5302] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
138
|
Motomura S, Fujisawa S, Anzai S, Fujimaki K, Hattori M, Fukawa H, Okubo T. [Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1995; 36:762-7. [PMID: 7563610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A 50-year-old female was admitted with acute promyelocytic leukemia (APL) in August, 1988. She was treated with behenoyl-ara-C, daunomycin, 6-mercaptopurine and prednisolone (BH-AC.DMP), which led to a complete remission. Thereafter, she was treated with 2 courses of BH-AC.DM and discharged from hospital. Intensification therapy was performed twice a year, with 1 course of BH-AC.DM and 5 courses of intermittent-dose ara-C/mitoxantrone which ended in March, 1992. She had a relapse in September, 1993 and was treated with all-trans retinoic acid, which led to a second remission. A second relapse occurred in May, 1994, and intermittent-dose ara-C/mitoxantrone, combined with granulocyte colony-stimulating factor (G-CSF), led to a third remission. However, she had a third relapse in September, 1994. She was treated with a trial of G-CSF (300 micrograms/body, day 1-7), to stimulate dormant leukemic cells to enter the cell cycle, and cyclosporin-A (78 mg/kg, day 2-5), in order to overcome daunomycin resistance in refractory leukemia, combined with daunomycin (45 mg/m2, day 3-5) and ara-C (1.4 g/m2, day 3-7), after obtaining informed consent. The fourth remission needed 46 days after combination chemotherapy because of severe myelosuppression. It was suggested that intermittent-dose ara-C/daunomycin therapy combined with G-CSF and cyclosporin-A may be useful for relapsed and refractory leukemia.
Collapse
|
139
|
Motomura S, Fujisawa S, Fujimaki K, Mohri H, Okubo T. Interstitial pneumonia induced by combination therapy with low-dose cytarabine and granulocyte colony-stimulating factor. Am J Hematol 1995; 49:364. [PMID: 7543731 DOI: 10.1002/ajh.2830490429] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
140
|
Maruta A, Matsuzaki M, Miyashita H, Kodama F, Kato H, Taguchi J, Tomita N, Sakai R, Fujisawa S, Okubo T. Successful pregnancy after allogeneic bone marrow transplantation following conditioning with total body irradiation. Bone Marrow Transplant 1995; 15:637-8. [PMID: 7655393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A 23-year-old woman had a normal full-term delivery 78 months after BMT for ALL. Conditioning therapy was Ara C 1.4 g/m2 x 4, CY 60 mg/kg x 2 and TBI 2.5 Gy x 5 at a dose rate of 3.5 cGy/min. Despite GVHD prophylaxis with short-term MTX and CsA, she developed grade I acute GVHD, but showed no evidence of chronic GVHD. Following amenorrhea for 4 years, menstruation recommenced spontaneously. She had a normal pregnancy 6 years after BMT resulting in a healthy infant with simple hypospadias. This and previous reports indicate that normal pregnancy is possible after BMT with TBI in excess of 10 Gy.
Collapse
|
141
|
Fujisawa S, Kishi E, Sugawara Y, Morita S. Atomic-scale friction observed with a two-dimensional frictional-force microscope. PHYSICAL REVIEW. B, CONDENSED MATTER 1995; 51:7849-7857. [PMID: 9977369 DOI: 10.1103/physrevb.51.7849] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
142
|
Fujisawa S, Maruta A, Ogawa K, Sakai R, Taguchi J, Tomita N, Kodama F, Sasaki S, Fukawa H, Murata T. [Treatment for elderly patients with acute non-lymphocytic leukemia]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1995; 36:91-7. [PMID: 7715090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A retrospective analysis was performed on forty nine elderly (34 males and 15 females) patients aged 65 years or more (median age 73, range 65-82) with acute non-lymphocytic leukemia (ANLL). Patients were studied to examine factors according to age group (65-69 years, 70-74, 75-79 and 80 or over), respectively. Patients were treated with either low dose Ara-C therapy or BHAC-DMP therapy according of the choice of their attending physicians. Complete remission (CR) was obtained in 20 of 49 patients (43%), and in 6 of 14 patients (43%) aged 65-69, in 8 of 18 (44%) aged 70-74, in 5 of 12 (42%) aged 75-79 years and in 1 of 3 (33%) aged 80 or over, respectively. The median survivals of these groups were 263, 298, 260, 168.5 and 38.5 days, respectively. Multivariate analysis revealed that the achievement of CR was associated with normal karyotype, and serum GOT level < or = 30 mu/ml and GPT < or = 40 mu/ml. Prolonged survival was related to the achievement of CR. The results indicated that liver function before chemotherapy was an important prognostic factor.
Collapse
|
143
|
Tachikawa T, Ishibashi Y, Fujisawa S, Takazawa S, Nyunt AK, Miyanaga Y. [A nation-wide survey on the occurrence of amoebic keratitis in Japan]. NIPPON GANKA GAKKAI ZASSHI 1995; 99:68-75. [PMID: 7887330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Acanthamoeba keratitis in Japan was first reported by Ishibashi in 1988. Since then, the incidence of Acanthamoeba keratitis has gradually increased. We retrospectively analyzed 39 cases, 42 eyes, of amoebic keratitis reported in Japan from 1988 to September 1993. Of the 39 patients, 35 (89.7%) wore contact lenses, 32 (82.1%) soft contact lenses, and 3 (7.7%) hard contact lenses, and 4 (10.3%) did not wear contact lenses. Of the 4 patients without contact lenses, 3 had a history of trauma. Acanthamoeba keratitis is often difficult to diagnose. Twenty-four cases were misdiagnosed as herpetic keratitis. Early diagnosis and adequate therapy are important.
Collapse
|
144
|
Fujisawa S, Kanamori H, Noguchi T, Maruta A, Ogawa K, Sakai R, Taguchi J, Tomita N, Kodama F, Okubo T. [Hypoplastic leukemia achieved long-term remission with low-dose cytosine arabinoside]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1995; 36:56-8. [PMID: 7715078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A 74-year-old woman was admitted in October 1988 with anemia and leukocytopenia. Hematologic investigations established a diagnosis of hypoplastic acute leukemia. She received a low dose of cytosine arabinoside (LDAC: 10 mg/m2 every 12 hours) subcutaneously for 21 days and achieved complete remission (CR) one month later. After one course of LDAC of 14 days, she received LDAC of 21 days every 5 to 6 months as maintenance therapy till April 1993. She has been in remission for 6 years. Intensification therapy with LDAC every 5 to 6 months might be useful in maintaining remission for hypoplastic acute leukemia.
Collapse
|
145
|
Abstract
2, 2-Bis [4- (2-hydroxy-3-methacryloyloxypropoxy) phenyl] propane (bis-GMA) is widely used in dentistry as a monomer of composite resin system and their bonding agents. Since bis-GMA is not purified, its isomers and some chemicals such as residual initiator remain in the commercial product. Bis-GMA and iso-bis-GMA were separated from bis-GMA monomer by HPLC. NMR spectra of both monomers were recorded, and their all signals in 1H and 13C-NMR spectra were assigned using DEPT and COSY experiments.
Collapse
|
146
|
Kitagaki H, Fujita K, Fujisawa S, Kitazawa T, Watanabe K, Shiohara T. Development of immediate-type hypersensitivity in the chronic phase of contact dermatitis in mice: A potential animal model for atopic dermatitis. J Dermatol Sci 1994. [DOI: 10.1016/0923-1811(94)90324-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
147
|
Kobayashi S, Yamamoto T, Akiba C, Katayama N, Sakai K, Maruta A, Ogawa K, Fujisawa S, Sakai R, Taguchi J. [Auer-rod-like bodies in plasma cells in patient with plasma cell dyscrasia]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1994; 35:713-6. [PMID: 8065027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Auer-rod-like bodies were found in plasma cells from a 74-year-old man with plasma cell dyscrasia. These bodies exhibited red purple staining by May-Giemsa staining and were indistinguishable from Auer bodies often found in acute myeloid leukemia. These bodies, however, failed to stain with peroxidase and showed acid phosphatase positivity. Bone marrow examinations were performed three times at the sternum or iliac crest. The proportions of plasma cells were 4.4%, 3.4% and 3.8%. The Auer-rod-like bodies were found in 0.05% (2/3824), 0.07% (4/6883) and 0.08% (2/2656) of the plasma cells.
Collapse
|
148
|
Maruta A, Kanamori H, Fukawa H, Harano H, Matsuzaki M, Miyashita H, Fujisawa S, Noguchi T, Ogawa K, Sakai R. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant 1994; 13:417-22. [PMID: 8019465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We used the polymerase chain reaction (PCR) to determine the presence of hepatitis C virus (HCV)-RNA in serum samples obtained from 19 patients with leukaemia or severe aplastic anaemia and investigated the correlation between HCV status and the results of liver function tests after bone marrow transplantation. PCR analysis of serum samples obtained before transplant showed that 10 of 18 patients were HCV-RNA-positive; 5 of these patients had developed acute post-transfusion hepatitis 1-11 months before transplant. An additional patient was HCV-RNA-positive on post-transplant day 62. Eight HCV-RNA-positive patients had pre-transplant GPT levels above the upper limit of normal. In these patients the GPT decreased significantly from a median of 104 IU/l (54-822 IU/l) pre-transplant to 23 IU/l (15-56 IU/l) on post-transplant days 8-12. In 9 of 11 HCV-RNA-positive patients, the GPT increased transiently from days 40 to 50 and again increased after day 100. Two of these patients died from hepatic failure; the GPT levels normalised in 3 patients after day 300 but continued to fluctuate in 4 patients. In the remaining 2 HCV-RNA-positive patients, the GPT remained close to the normal range throughout the follow-up period. Three HCV-RNA-positive patients became HCV-RNA-negative after 1-3 years. In these patients, the GPT remained normal for > 3 years after day 300.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
149
|
Kobayashi A, Fujisawa S. Effect of L-carnitine on mitochondrial acyl CoA esters in the ischemic dog heart. J Mol Cell Cardiol 1994; 26:499-508. [PMID: 8072006 DOI: 10.1006/jmcc.1994.1060] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Many studies have shown that L-carnitine has a positive effect on ischemic myocardium, probably by reducing accumulation of long-chain acyl coenzyme A (CoA) esters. Previous studies have involved whole-heart extracts and have not assessed changes of CoA ester levels in mitochondria, the site of translocase inhibition. To more precisely assess L-carnitine effects, we measured long-chain acyl CoA ester levels in cytosol and in mitochondria in the ischemic canine heart. Dogs were divided into four groups: a sham-operated control group; an untreated group; and high- and low-dose L-carnitine-treated groups (30 mg/kg and 100 mg/kg). After 60 min of ischemia, the heart was excised, and the cytosolic and mitochondrial fractions were isolated. CoA esters and the activity of carnitine palmitoylcarnitine transferase (CPT) I and II were measured in both compartments. Approximately 89% of cellular free CoA. 90% of cellular acetyl CoA, 97% of cellular shot-chain acyl CoA, and 92% of cellular long-chain acyl CoA were located in the mitochondrial space under the normal condition. Under the ischemic condition, mitochondrial free CoA was significantly decreased. Conversely, mitochondrial acetyl CoA and long-chain acyl CoA were significantly increased. Treatment with L-carnitine significantly decreased acetyl CoA and long-chain acyl CoA in the ischemic mitochondrial space in a dose-dependent manner. These results support the hypothesis that L-carnitine reduces accumulation of long-chain acyl CoA within the ischemic mitochondrial space and thereby improves mitochondrial function and adenine nucleotide translocation.
Collapse
|
150
|
Kobayashi S, Yamamoto T, Akiba C, Katayama N, Sakai K, Yamaguchi M, Maruta A, Ogawa K, Fujisawa S, Sakai R. [CD14-positive and nonspecific esterase-positive neutrophils in a patient with refractory anemia with excess of blasts in transformation]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1993; 34:1474-9. [PMID: 7504751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
A 34-year-old man was admitted with lumbago and anemia in November 1992. Hematological examination revealed an Hb 9.2g/dl, WBC count 13,500 microliters (33% blasts), and monocyte count 3,400/microliters. Bone marrow examination showed hyperplasia with dysplasia in trilineage blood cells and increased blasts (21.8%). A diagnosis of refractory anemia with excess of blasts in transformation (RAEB in T) was made. Cytochemical examination revealed the neutrophils in the peripheral blood were 66.5% positive for alpha-naphthyl butyrate esterase inhibited by sodium fluoride, 4.0% positive for peroxidase and 75% positive for alkaline phosphatase. The results of immuno-alkaline phosphatase stainings (avidin biotin alkaline phosphatase complex method) of neutrophils were as follows; CD16 (94.5%), CD24 (91.0%), CD13 (93.0%), CD14 (52.5%), CD33 (39.0%), CD36 (16.5%), HLA-DR (17.0%). These neutrophils exhibited monocyte-specific features and failed to show characteristics of neutrophils.
Collapse
|